How long is a standard KLOW cycle
In the SUSTAIN clinical trial program evaluating injectable semaglutide for type 2 diabetes, gastrointestinal adverse events occurred in 3050% of participants, with nausea being most common
Pharmacological interventions are considered only when lifestyle measures have been insufficient and specific BMI thresholds are met
The Bottom Line (Plain English) Weeks 12: appetite changes, little scale movement Weeks 36: weight loss often begins Months 36: meaningful, sustained loss for many Semaglutide: slower start, steady progress Tirzepatide: faster early loss for some, same long-term rules apply GLP-1 rewards patience not urgency
Studies examining patients on antidepressants who started GLP-1 receptor agonists found that those on bupropion specifically tended to fare better in terms of weight loss compared to those on SSRIs like sertraline or fluoxetine
You should discuss alternatives with your prescriber if: Severe reflux persists despite maximum medical therapy (twice-daily PPI plus lifestyle modifications) for more than 8 weeks